Fiche centre
Vancouver General Hospital
Vancouver — Canada
Essais liés7clinical trials
VilleVancouverlocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05069558
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Physiology-guided NCL PCI | Maladie coronarienne | Non applicable | NCT05701358 | COMPLETE-2 — Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | ACTIVE_NOT_RECRUITING |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Recombinant Factor VIIa | Accident vasculaire cérébral | Phase 3 | NCT07227246 | FASTEST Part 2 — Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 | RECRUITING |
| Active Colchicine | Maladie coronarienne | Phase 3 | NCT03310125 | Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) | COMPLETED |
| Investigational PFO Closure Device | Accident vasculaire cérébral | Non applicable | NCT05069558 | OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | ACTIVE_NOT_RECRUITING |
| Aminophylline (250mg IV +/- a second dose of 250mg IV) | SEP | Phase 2 | NCT00312273 | Aminophylline in Bradyasystolic Cardiac Arrest | COMPLETED |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |